Related Experiment Videos

Antihypertensive medications for risk reduction of first and recurrent ischemic stroke

Vasamtha Padma1, Marc Fisher, Majaz Moonis

  • 1All India Institute of Medical Sciences, New Delhi, India. vasamtha.padma@hotmail.com

Expert Review of Cardiovascular Therapy
|October 27, 2004
PubMed

Insights

Lowering blood pressure significantly reduces vascular events like ischemic stroke. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers show superior stroke prevention compared to other antihypertensives.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Hypertension management is crucial for vascular event prevention.
  • Ischemic stroke remains a leading cause of morbidity and mortality.
  • Identifying optimal antihypertensive strategies is a priority.

Purpose of the Study:

  • To review the evidence for angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in stroke prevention.
  • To assess the comparative effectiveness of ACEIs/ARBs versus other antihypertensives for stroke risk reduction.
  • To evaluate the scientific rationale for using ACEIs/ARBs in primary and secondary stroke prevention.

Main Methods:

  • Systematic review of prospective comparative trials.
  • Analysis of randomized controlled trials comparing ACEIs/ARBs with other antihypertensive drug classes.
  • Critical appraisal of the scientific literature on stroke prevention.

Main Results:

  • Small reductions in blood pressure lead to substantial risk reduction of vascular events, including ischemic stroke.
  • ACEIs and ARBs demonstrated a greater effect on preventing primary and recurrent ischemic stroke compared to other antihypertensives, for equivalent blood pressure reduction.
  • Prospective randomized trials support the efficacy of ACEIs and ARBs in stroke prevention.

Conclusions:

  • ACEIs and ARBs should be considered first-line treatment for hypertension in patients at risk of ischemic stroke.
  • These drug classes offer a favorable risk-benefit profile for stroke prevention.
  • Further research may refine the role of ACEIs and ARBs in diverse patient populations.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.